Pharmaron Beijing Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Beijing, Beijing and currently employs 21,370 full-time employees. The company went IPO on 2019-01-28. Pharmaron Beijing Co Ltd is a China-based company mainly engaged in pharmaceutical research and development. The firm operates through five segments. The Laboratory Services segment includes laboratory chemistry and bioscience services, covering small molecule drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates, and cell and gene therapy products. The Chemical and Formulation Process Development and Manufacturing Services segment includes active pharmaceutical ingredient process development and manufacturing, as well as preformulation and formulation development. The Clinical Research Services segment includes international and domestic clinical research services. The Large Molecule and Cell and Gene Therapy Services segment includes large molecule drug discovery, development, and manufacturing services, as well as cell and gene therapy laboratory and gene therapy drug development and manufacturing services. The firm also operates through the others segment.
Follow-Up Questions
¿Quién es el CEO de Pharmaron Beijing Co Ltd?
Mr. Boliang Lou es el Executive Chairman of the Board de Pharmaron Beijing Co Ltd, se unió a la empresa desde 2016.
¿Qué tal es el rendimiento del precio de la acción PHBBF?
El precio actual de PHBBF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Pharmaron Beijing Co Ltd?
Pharmaron Beijing Co Ltd pertenece a la industria Life Sciences Tools & Services y el sector es Health Care
¿Cuál es la capitalización bursátil de Pharmaron Beijing Co Ltd?
La capitalización bursátil actual de Pharmaron Beijing Co Ltd es $0
¿Es Pharmaron Beijing Co Ltd una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 14 analistas han realizado calificaciones de análisis para Pharmaron Beijing Co Ltd, incluyendo 5 fuerte compra, 9 compra, 3 mantener, 2 venta, y 5 fuerte venta
